Food by-products have been used as source of bioactive compounds with health benefits. Supercritical carbon dioxide (SC-CO2) extraction has been a valuable technology to obtain a diversity of ...bioactive compounds with the use of safer solvents. This research focused on the comparison of the antioxidant, anti-inflammatory and antihyperglycemic activities of SC-CO2 and conventional extracts obtained from black bean by-products. A Box-Behnken design was used to evaluate the effect of temperature, pressure, and co-solvent on the soyasaponins recovery. Total phenolic compounds (TPC) were quantified using Folin-Ciocalteu. Cellular antioxidant activity (CAA) and anti-inflammatory response via nitric oxide (NO) assay were evaluated in vitro. The antihyperglycemic activity was evaluated using digestive enzymes. The highest soyasaponin extraction yield was obtained at 70 °C, 10 MPa and 10% co-solvent. SC-CO2 extracts exhibited up to 74.7% of CAA, an inhibition of 93.0% NO, 25.1% α-amylase, 78.7% α-glucosidase and 82.33 ± 5.80 of TPC. SC-CO2 extraction resulted in a feasible technology to obtain high-value compounds from industrial by-products to treat hyperglycemic, oxidative stress and inflammation.
Display omitted
•SC-CO2 mixed with co-solvent is a feasible technique to obtain rich soyasaponins extracts from black bean by-products.•Recovery of Ba (V) and αg soyasaponins from black bean by-product extracts is favored at 70°C, 10 MPa and 10% co-solvent.•Extraction at 55 °C, 10 MPa and 5% co-solvent showed the highest extraction selectivity of Ba (V) and αg soyasaponins.•SC-CO2 with co-solvent is a feasible technique to obtain extracts with a higher content of TPC from black bean by-products.•The antioxidant, anti-inflammatory and antihyperglycemic activities were correlated with soyasaponin Ba (V), αg and TPC.
Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 varies widely in its presentation and severity, with low mortality in high-income countries. In this ...study in 16 Latin American countries, we sought to characterize patients with MIS-C in the pediatric intensive care unit (PICU) compared with those hospitalized on the general wards and analyze the factors associated with severity, outcomes, and treatment received.
An observational ambispective cohort study was conducted including children 1 month to 18 years old in 84 hospitals from the REKAMLATINA network from January 2020 to June 2022.
A total of 1239 children with MIS-C were included. The median age was 6.5 years (IQR 2.5-10.1). Eighty-four percent (1043/1239) were previously healthy. Forty-eight percent (590/1239) were admitted to the PICU. These patients had more myocardial dysfunction (20% vs 4%;
< 0.01) with no difference in the frequency of coronary abnormalities (
= 0.77) when compared to general ward subjects. Of the children in the PICU, 83.4% (494/589) required vasoactive drugs, and 43.4% (256/589) invasive mechanical ventilation, due to respiratory failure and pneumonia (57% vs 32%;
= 0.01). On multivariate analysis, the factors associated with the need for PICU transfer were age over 6 years (aOR 1.76 95% CI 1.25-2.49), shock (aOR 7.06 95% CI 5.14-9.80), seizures (aOR 2.44 95% CI 1.14-5.36), thrombocytopenia (aOR 2.43 95% CI 1.77-3.34), elevated C-reactive protein (aOR 1.89 95% CI 1.29-2.79), and chest x-ray abnormalities (aOR 2.29 95% CI 1.67-3.13). The overall mortality was 4.8%.
Children with MIS-C who have the highest risk of being admitted to a PICU in Latin American countries are those over age six, with shock, seizures, a more robust inflammatory response, and chest x-ray abnormalities. The mortality rate is five times greater when compared with high-income countries, despite a high proportion of patients receiving adequate treatment.
PDF